Brand Name(s):Adakveo

Indication:Prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older.



Review Date:Nov-26

NICE TA743 – Crizanlizumab for preventing sickle cell crises in sickle cell disease – 1.1Crizanlizumab is recommended as an option for preventing recurrent sickle cell crises (vaso-occlusive crises) in people aged 16 or over with sickle cell disease only if the conditions in the managed access agreement are followed.

1.2 This recommendation is not intended to affect treatment with crizanlizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.